By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- A new study on Biotechnology is now available. According to news reporting originating in Seoul, South Korea, by NewsRx journalists, research stated, "Targeted therapy or molecular targeted therapy has been defined as a type of treatment that blocks the growth of cancer cells by interfering with specific cell molecules required for carcinogenesis and tumor growth, rather than by simply interfering with all rapidly dividing cells as with traditional chemotherapy. There is a growing number of FDA approved monoclonal antibodies and small molecules targeting specific types of cancer suggestive of the growing relevance of this therapeutic approach."
The news reporters obtained a quote from the research from CHA University, "Targeted cancer therapies, also referred to as 'Personalized Medicine', are being studied for use alone, in combination with other targeted therapies, and in combination with chemotherapy. The objective of personalized medicine is the identification of patients that would benefit from a specific treatment based on the expression of molecular markers. Examples of this approach include bevacizumab and olaparib, which have been designated as promising targeted therapies for ovarian cancer. Combinations of trastuzumab with pertuzumab, or T-DM1 and mTOR inhibitors added to an aromatase inhibitor are new therapeutic strategies for breast cancer. Although this approach has been seen as a major step in the expansion of personalized medicine, it has substantial limitations including its high cost and the presence of serious adverse effects. The Cancer Genome Atlas is a useful resource to identify novel and more effective targets, which may help to overcome the present limitations. In this review we will discuss the clinical outcome of some of these new therapies with a focus on ovarian and breast cancer."
According to the news reporters, the research concluded: "We will also discuss novel concepts in targeted therapy, the target of cancer stem cells."
For more information on this research see: Targeted cancer therapy - Are the days of systemic chemotherapy numbered? Maturitas, 2013;76(4):308-314. Maturitas can be contacted at: Elsevier Ireland Ltd, Elsevier House, Brookvale Plaza, East Park Shannon, Co, Clare, 00000, Ireland. (Elsevier - www.elsevier.com; Maturitas - www.elsevier.com/wps/product/cws_home/505954)
Our news correspondents report that additional information may be obtained by contacting W.D. Joo, CHA Univ, CHA Gangnam Med Center, Dept. of Obstet & Gynecol, Seoul, South Korea. Additional authors for this research include I. Visintin and G. Mor (see also Biotechnology).
Keywords for this news article include: Asia, Biotechnology, Seoul, Drugs, Genetics, Oncology, Treatment, South Korea, Chemotherapy, Cancer Gene Therapy, Personalized Medicine
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC